ILND Surgery Alone or after Chemotherapy with or without Radiation Therapy in Treating Patients with Advanced Penile Cancer

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Status: Active


This phase III randomized trial studies how well inguinal lymph node dissection (ILND) surgery alone or after chemotherapy with or without intensity-modulated radiation therapy works in treating patients with penile cancer that has spread to other places in the body. Surgery is used to remove the lymph nodes and may be able to cure the cancer. Drugs used in chemotherapy, such as paclitaxel, ifosfamide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Intensity-modulated radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. It is not known whether having surgery after chemotherapy with or without radiation therapy is better than having surgery alone.

Eligibility Criteria

Inclusion Criteria

  • Histologically-proven squamous cell carcinoma of the penis
  • Stage: * any T, N1 (i.e. a palpable mobile unilateral inguinal lymph node), M0, or; * any T, N2 (i.e. palpable mobile multiple or bilateral inguinal lymph nodes), M0, or; * any T, N3 (i.e. fixed inguinal nodal mass or any pelvic lymphadenopathy), M0
  • Measurable disease as determined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1) criteria
  • Performance status Eastern Cooperative Oncology Group (ECOG) 0, 1, or 2
  • Patient is fit to receive the randomization options for which he is being considered
  • Hematology/biochemistry (as dictated by local hospital practice) should indicate fitness for randomization options and parameters should be in line with considerations specified in the summary of product characteristics; hematological parameters should not be supported by transfusion to enable entry into the trial; liver function and renal function tests must form part of the pre-treatment assessment for patients who may be randomized to receive paclitaxel, ifosfamide, and cisplatin (TIP) chemotherapy e.g. patients with impaired renal function may not be considered for arms B and C of InPACT-neoadjuvant but may be considered for arm A
  • Willing and able to comply with follow-up schedule
  • Written informed consent

Exclusion Criteria

  • Pure verrucous carcinoma of the penis
  • Non-squamous malignancy of the penis
  • Squamous carcinoma of the urethra
  • Stage M1
  • Previous chemotherapy or chemoradiotherapy outside of the InPACT trial
  • Concurrent malignancy (other than squamous cell carcinoma [SCC] or basal cell carcinoma of non-penile skin) that has required surgical or non-surgical treatment in the last 3 years
  • Patients who are sexually active and unwilling to use effective contraception (if they are not already surgically sterile)

Locations & Contacts


Emory University Hospital / Winship Cancer Institute
Status: Active
Contact: Viraj Master
Phone: 404-778-1868
Grady Health System
Status: Active
Contact: Viraj Master
Phone: 404-489-9164


ECOG-ACRIN Cancer Research Group
Status: Active
Contact: Curtis A. Pettaway
Phone: 713-792-3245


M D Anderson Cancer Center
Status: Active
Contact: Curtis A. Pettaway
Phone: 713-792-3245

Trial Objectives and Outline


I. To determine if there is a role for neoadjuvant therapy and if so, whether chemotherapy or chemoradiotherapy produce superior outcomes (either for survival endpoints or for morbidity/quality of life endpoints).

II. To determine the additional survival benefit of prophylactic pelvic lymph node dissection (PLND) given after neoadjuvant chemoradiotherapy or with adjuvant chemoradiotherapy of the pelvic nodes over and above that of chemoradiotherapy alone in patients at high risk of recurrence following inguinal lymph node dissection (ILND).


I. To determine if neoadjuvant therapy prior to surgery (ILND) can reduce recurrence rates. (International Penile Advanced Cancer Trial [InPACT]-neoadjuvant)

II. To determine which is the more active of neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy. (InPACT-neoadjuvant)

III. To determine the operative/post-operative complication rate following neoadjuvant therapy of both types. (InPACT-neoadjuvant)

IV. To determine if neoadjuvant chemoradiotherapy is feasible in this setting. (InPACT-neoadjuvant)

V. To determine the rate of additional complications for the combination of PLND and chemoradiotherapy. (InPACT‐pelvis)


I. To determine the relationship between human papillomavirus (HPV) status and outcome for all groups studied.

II. To determine the impact on quality of life of the (sequential) treatments studied.


InPACT-NEOADJUVANT: Patients are randomized to 1 of 3 arms.

Arm A: Patients undergo standard of care ILND surgery.

Arm B: Patients receive paclitaxel intravenously (IV) over 3 hours on day 1, cisplatin IV over 2 hours on days 1-5 or 1-3, and ifosfamide IV over 1 hour on days 2-5 or 1-3. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Approximately 6-12 weeks after day 1 of the last course of neoadjuvant chemotherapy, patients undergo ILND surgery.

Arm C: Beginning 4 weeks after randomization, patients receive cisplatin IV and undergo intensity-modulated radiation therapy (IMRT) for 25 fractions over 5 weeks. Approximately 6 weeks after completion of neoadjuvant chemotherapy and IMRT, patients undergo ILND surgery.

InPACT-PELVIS: Patients with pathological high risk are randomized to 1 of 2 arms.

Arm P: Patients undergo PLND surgery. Beginning 8 weeks after PLND surgery, patients who have not received neoadjuvant chemotherapy and IMRT, receive cisplatin IV and undergo IMRT for 25 fractions over 5 weeks.

ARM Q: Patients undergo surveillance at fixed time-points according to local practice. Beginning 8 weeks after ILND surgery, patients who have not received neoadjuvant chemotherapy and IMRT, receive cisplatin IV and undergo IMRT for 25 fractions over 5 weeks.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.

Trial Phase & Type

Trial Phase

Phase III

Trial Type


Lead Organization

Lead Organization
ECOG-ACRIN Cancer Research Group

Principal Investigator
Curtis A. Pettaway

Trial IDs

Primary ID EA8134
Secondary IDs NCI-2016-01502 ID NCT02305654